We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+433.28%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
989

Sector Composition

Rank Sector Weight
1 Technology 6.08%
2 Financials 6.03%
3 Industrials 5.01%
4 Consumer Discretionary 4.73%
5 Healthcare 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HSTO
7401
DELISTED
Histogen Inc. Common Stock
HSTO
$62K ﹤0.01%
67
-132
-66% -$122K
ROX
7402
DELISTED
Castle Brands, Inc.
ROX
$62K ﹤0.01%
+51,201
New +$63.6K
HGT
7403
DELISTED
Hugoton Royalty Trust
HGT
$62K ﹤0.01%
+44,420
New +$70.1K
DRD
7404
DRDGold
DRD
$1.77B
$61K ﹤0.01%
+18,770
New +$64.4K
TANH icon
7405
Tantech Holdings
TANH
$6.07M
$61K ﹤0.01%
+2
New +$54.1K
XBIT icon
7406
PUT
XBiotech
XBIT
$68M
$61K ﹤0.01%
15,600
-9,000
-37% -$37.9K
NVLN
7407
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$61K ﹤0.01%
+19,655
New +$94.5K
AUPH icon
7408
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
$60K ﹤0.01%
13,200
-77,900
-86% -$432K
CASI
7409
DELISTED
CASI Pharmaceuticals
CASI
$60K ﹤0.01%
+1,840
New +$50K
IPI icon
7410
PUT
Intrepid Potash
IPI
$456M
$60K ﹤0.01%
1,270
-2,620
-67% -$102K
NXE icon
7411
NexGen Energy
NXE
$6.06B
$60K ﹤0.01%
+23,500
New +$54.6K
ENFY
7412
DELISTED
Enlightify Inc
ENFY
$60K ﹤0.01%
4,005
+401
+11% +$6.07K
ARAV
7413
DELISTED
Aravive, Inc. Common Stock
ARAV
$60K ﹤0.01%
4,545
+314
+7% +$4.04K
AGTC
7414
DELISTED
Applied Genetic Technologies Corporation
AGTC
$60K ﹤0.01%
16,533
-24,737
-60% -$93.4K
CSLT
7415
CALL
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$60K ﹤0.01%
+16,100
New +$64.5K
BIOA
7416
DELISTED
BioAmber Inc.
BIOA
$60K ﹤0.01%
+149,504
New +$71.1K
BCLI
7417
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$59K ﹤0.01%
1,002
+15
+2% +$897
BCRX icon
7418
PUT
BioCryst Pharmaceuticals
BCRX
$2.28B
$59K ﹤0.01%
12,100
-26,100
-68% -$126K
VIVS
7419
PUT
VivoSim Labs
VIVS
$1.2M
$59K ﹤0.01%
184
+24
+15% +$8.92K
AVID
7420
PUT
DELISTED
Avid Technology Inc
AVID
$59K ﹤0.01%
+10,900
New +$58.6K
CELH icon
7421
Celsius Holdings
CELH
$7.47B
$58K ﹤0.01%
+32,961
New +$57.8K
NOG icon
7422
PUT
Northern Oil and Gas
NOG
$2.3B
$58K ﹤0.01%
+2,830
New +$34.2K
VJET
7423
CALL
DELISTED
VOXELJET AG American Depositary Shares (each representing one Ordinary Share)
VJET
$58K ﹤0.01%
+2,560
New +$65.6K
APEX
7424
DELISTED
Apex Global Brands Inc. Common Stock
APEX
$58K ﹤0.01%
+1,010
New +$70.6K
ENT
7425
PUT
DELISTED
Global Eagle Entertainment Inc.
ENT
$58K ﹤0.01%
1,012
+448
+79% +$29.1K

Similar funds

Citadel Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Citadel Advisors held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Citadel Advisors deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, down from 7% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Citadel Advisors's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Citadel Advisors added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Citadel Advisors fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Citadel Advisors's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Citadel Advisors opened 1,440 new positions and closed 989 in Q4 2017.
  • Citadel Advisors's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.